Plecanatide Patent Expiration
Plecanatide is Used for treating chronic idiopathic constipation, irritable bowel syndrome with constipation by increasing intracellular cGMP levels to improve intestinal function. It was first introduced by Salix Pharmaceuticals Inc
Plecanatide Patents
Given below is the list of patents protecting Plecanatide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Trulance | US10011637 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | Jun 05, 2034 | Salix |
| Trulance | US11142549 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | Jun 05, 2034 | Salix |
| Trulance | US11834521 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | Jun 05, 2034 | Salix |
| Trulance | US9616097 | Formulations of guanylate cyclase C agonists and methods of use | Aug 20, 2032 | Salix |
| Trulance | US11319346 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | Mar 01, 2032 | Salix |
| Trulance | US9610321 | Formulations of guanylate cyclase C agonists and methods of use | Sep 15, 2031 | Salix |
| Trulance | US9919024 | Formulations of guanylate cyclase C agonists and methods of use | Sep 15, 2031 | Salix |
| Trulance | US9925231 | Formulations of guanylate cyclase C agonists and methods of use | Sep 15, 2031 | Salix |
| Trulance | US7041786 | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis | Jan 30, 2028 | Salix |
| Trulance | US7799897 | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Jun 09, 2022
(Expired) | Salix |
| Trulance | US8637451 | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Mar 28, 2022
(Expired) | Salix |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Plecanatide's patents.
Latest Legal Activities on Plecanatide's Patents
Given below is the list recent legal activities going on the following patents of Plecanatide.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Sequence Moved to Public Database | 08 Dec, 2023 | US11834521 |
| Recordation of Patent eGrant | 05 Dec, 2023 | US11834521 |
| Email Notification Critical | 05 Dec, 2023 | US11834521 |
| Recordation of Patent Grant Mailed Critical | 05 Dec, 2023 | US11834521 |
| Mail Patent eGrant Notification | 05 Dec, 2023 | US11834521 |
| Patent Issue Date Used in PTA Calculation Critical | 05 Dec, 2023 | US11834521 |
| Patent eGrant Notification | 05 Dec, 2023 | US11834521 |
| Email Notification Critical | 16 Nov, 2023 | US11834521 |
| Issue Notification Mailed Critical | 15 Nov, 2023 | US11834521 |
| Application Is Considered Ready for Issue Critical | 06 Nov, 2023 | US11834521 |
Plecanatide's Family Patents
